Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|May 12, 2014
Novartis and Servier in Oncology Collaboration
Author(s)Pharmaceutical Executive
Novartis has teamed with the French drug maker Servier to develop and commercialize novel drug candidates targeting apoptosis in oncology.
Advertisement
Novartis has teamed with the French drug maker Servier to develop and commercialize novel drug candidates targeting apoptosis in oncology.
The collaboration covers BCL-2 selective inhibitor candidates - developed by Servier and Vernalis - currently entering clinical development. Proteins of the BCL-2 family are crucial regulators of apoptosis (programmed cell death).
“These new compounds further extends Servier’s portfolio beyond kinase inhibitors, HDAC inhibitors and immunitherapeutic products,” said Dr Jean-Pierre Abastado of Servier’s Center of Therapeutic Innovation in Oncology.
Advertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
2
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
3
Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica
4
Evidence With Purpose: Making Real-World Research Better, Not Just Faster
5